UK-based life sciences firm Abzena says that its US biomanufacturing subsidiary PacificGMP has made two senior appointments to support its growth. 23 February 2016
In our weekly expert view piece, Andrew Nichols, Tungsten Analytics lead and head of procurement, examines how the pharmaceutical industry can reduce its spending waste. 23 February 2016
A new life sciences investment company, which includes former senior pharma industry executive, has commenced operations with initial funding from institutional investors. 22 February 2016
In our weekly expert view piece, John Kokai-Kun, PhD, vice-president of non-clinical affairs at Synthetic Biologics, examines a new way to extend the life and use of current antibiotics. 12 February 2016
US pharma giant Pfizer has named the executive leadership team that will take up the reins after its acquisition of Irish-based Allergan is finalised at the end of this year. 9 February 2016
In our weekly expert view piece, John Maloney, commerical product director at Bloomberg BNA and editors of Bloomberg Law: corporate transactions, examines the proposed Shire-Baxalta merger. 9 February 2016
Astellas Pharma has announced the promotion of James Robinson as president, Americas operations, for Astellas US, with responsibility for the company's operations in North and South America, effective April 1, 2016. 8 February 2016
Privately-held Swiss biotech firm MaxiVAX SA has appointed Dimitrios Goundis as its chief executive. Dr Goundis joins the company after holding several senior management and R&D positions at The Medicines Company, Speedel and Roche, both in Europe and the USA. 8 February 2016
French drug major Sanofi on Friday named Muzammil Mansuri executive vice president, strategy & business development, effective February 22, 2016. 5 February 2016
The dust has yet to settle on a report warning that the international community is ill-prepared to face another infectious disease outbreak and suddenly we are staring down the barrel of a Zika pandemic. 1 February 2016
Gilead Sciences Inc on Friday said chief operating officer John Milligan will be promoted to chief executive, replacing the current chairman and CEO John Martin who will take on the role of executive chairman, both effective March 10, 2016. 29 January 2016
The newly-appointed chief executive of US-based firm Avanir Pharmaceuticals has set out his vision in an exclusive interview with The Pharma Letter’s Katie Osborne. 29 January 2016
Swiss pharma major Novartis, along with its financial results (see separate story) this morning, announced a major changes for its underperforming ophthalmic business Alcon, as well as some senior management appointments. 27 January 2016
Germany’s Merck on Wednesday announced two appointments to head its businesses in North America and China in a bid to strengthen its position in the regions. 27 January 2016
Valeant Pharmaceuticals’ chief executive Michael Pearson has said he is on the road to recovery but that he was uncertain about when he would return from medical leave. 26 January 2016
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024